SCHEMBL20139480

SCHEMBL20139480

COc1cc(OCc2ccccc2)c(Br)cc1C(O)c1ccc2c(c1)CC2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.44
PTPN1 P18031 2/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
ABCB1 P08183 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
AGTR2 P50052 1/20 0.38
HRH3 Q9Y5N1 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TOP2A P11388 1/20 0.38
TOP2B Q02880 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMPD1 P17405 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20140068 0.88 HTR2A (0.42) CHRNA7PTPN1HTR2AHTR2CRAB9A
SCHEMBL20140032 0.86 HTR2A (0.41) CHRNA7PTPN1HTR2AHTR2CRAB9A
SCHEMBL20140108 0.86 HTR2A (0.41) CHRNA7PTPN1HTR2AHTR2CABCB1
SCHEMBL20140136 0.86 HTR2A (0.40) CHRNA7HTR2AHTR2CNPC1RAB9A
SCHEMBL20139486 0.86 HTR2A (0.40) CHRNA7HTR2AHTR2CNPC1RAB9A
SCHEMBL20139642 0.86 HTR2A (0.37) CHRNA7PTPN1HTR2AHTR2CRAB9A
SCHEMBL20141585 0.83 HTR2A (0.42) CHRNA7PTPN1HTR2AHTR2CRAB9A
SCHEMBL20139949 0.83 RAB9A (0.47) CHRNA7PTPN1HTR2AHTR2CRAB9A
SCHEMBL23700122 0.82 MAOB (0.46) PTPN1ABCB1NPC1RAB9AMEN1
SCHEMBL20139974 0.78 TOP2A (0.36) HTR2AHTR2CKMT2ATOP2ATOP2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 CHRNA7 3628/4885PTPN1 1940/4885HTR2A 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.